Results 161 to 170 of about 1,096 (177)

Anti-Inflammatory Effects of Varespladib Methyl in Diabetic Patients with Acute Coronary Syndrome

Cardiovascular Drugs and Therapy, 2011
Secretory phospholipase A(2) group IIA (sPLA(2-)IIA) concentration and activity are associated with increased risk of cardiovascular events in acute coronary syndrome (ACS) patients. This study evaluated baseline differences in sPLA(2)-IIA concentration and other inflammatory markers in ACS patients with and without diabetes, and the inflammatory ...
Robert S. Rosenson, Heather Fraser, Michael A. Goulder, Colin Hislop   +3 more
openalex   +3 more sources

Some of the next articles are maybe not open access.

Related searches:

Varespladib

American Journal Cardiovascular Drugs, 2011
Anthera Pharmaceuticals is developing an oral formulation of varespladib (A 001; A 002; A-001; A-002; LY 315920; LY 333013; LY315920; LY333013; S 3013; S 5920; S-3013; S-5920; Varespladib methyl) for once-daily treatment of acute coronary syndromes.
openaire   +2 more sources

Revealing the rationale behind the differential neutralization of phospholipase A2 (PLA2) enzymes in snake and bee venom by varespladib (LY-315920), a small molecule PLA2 inhibitor.

Journal of Biomolecular Structure and Dynamics
Phospholipase A2 (PLA2) enzyme found in snakes, bees, and wasps' venoms is responsible for toxicity and pathophysiology of envenomation. Varespladib (VP, LY-315920) is among the extensively researched small molecule inhibitors targeting snake venom (SV ...
Rahul Kumar, Aparup Patra, D. Das, K. Saikia, Joana R. da Silva, M. J. Ramos, M. R. Khan, P. A. Fernandes, Ashis K. Mukherjee   +8 more
semanticscholar   +1 more source

Varespladib Alleviates Colonic Inflammation Induced by High‐Fat Diet via Downregulating the TGF‐β/Smad Pathway and AA Pathway by Inhibiting sPLA2

Journal of Gastroenterology and Hepatology
High‐fat diets (HFD) increase the risk of colonic inflammation. Varespladib, an sPLA2 inhibitor, has shown potential to treat a variety of inflammatory diseases. Its role in colonic inflammation caused by a HFD remains to be studied.
Shirui Meng, Yuanyuan Li, Linfeng Wang, Jiahao Liu, Daixuan Zhou, Xiong Ying, Chunhong Huang   +6 more
semanticscholar   +1 more source

Ability of the phospholipase A2 inhibitor Varespladib to abrogate or delay lethality induced by neurotoxic snake venoms.

Toxicon, 2020
J. Gutiérrez, M. Lewin, David J. Williams, B. Lomonte   +3 more
semanticscholar   +2 more sources

After FRANCIS: Next Steps in the Clinical Evaluation of Varespladib Methyl

Future Cardiology, 2010
Secretory phospholipase A(2) (sPLA(2)) represents a family of isoenzymes that participate in lipoprotein and inflammatory pathways, mediate atherosclerosis and enhance myocardial ischemic injury. The Fewer Recurrent Acute Coronary Events with Near-term Cardiovascular Inflammatory Suppression (FRANCIS) trial (NCT00743925) was a Phase II trial designed ...
openaire   +2 more sources

Varespladib (A-002), a Secretory Phospholipase A2 Inhibitor, Reduces Atherosclerosis and Aneurysm Formation in ApoE− / − Mice

Journal of Cardiovascular Pharmacology, 2009
The family of secretory phospholipase A2 (sPLA2) enzymes has been associated with inflammatory diseases and tissue injury including atherosclerosis. A-001 is a novel inhibitor of sPLA2 enzymes discovered by structure-based drug design, and A-002 is the orally bioavailable prodrug currently in clinical development.
Heather, Fraser, Colin, Hislop, Robert M, Christie, Heather L, Rick, Charles A, Reidy, Michael L, Chouinard, Patrick I, Eacho, Kenneth E, Gould, Joaquim, Trias   +8 more
openaire   +2 more sources

Varespladib methyl, an oral phospholipase A2 inhibitor for the potential treatment of coronary artery disease.

IDrugs : the investigational drugs journal, 2009
Varespladib methyl is an oral secretory phospholipase A2 inhibitor that is being developed by Anthera Pharmaceuticals Inc for the potential treatment of coronary artery disease, acute coronary syndrome and inflammation. Varespladib methyl is a prodrug that is rapidly metabolized to varespladib, and both compounds are able to potently inhibit the ...
Mahir, Karakas, Wolfgang, Koenig
openaire   +1 more source

Effect of the phospholipase A2 inhibitor Varespladib, and its synergism with crotalic antivenom, on the neuromuscular blockade induced by Crotalus durissus terrificus venom (with and without crotamine) in mouse neuromuscular preparations.

Toxicon, 2022
Jocimar de Souza, I. C. Oliveira, E. H. Yoshida, Nathalia M. Cantuária, J. Cogo, Kristian A Torres-Bonilla, S. Hyslop, Nelson J. Silva Junior, R. S. Floriano, J. Gutiérrez, Y. Oshima-Franco   +10 more
semanticscholar   +1 more source

Adverse Effects Associated with Varespladib in the VISTA-16 Trial

MD Conference Express, 2013
M. Cunningham, S. J. Nicholls
openaire   +1 more source